LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, TRIGLYCERIDE-RICH LIPOPROTEINS, AND GLUCOSE TOLERANCE IN NON-DIABETIC MEN WITH ESSENTIAL HYPERTENSION

REFERENCES

• Stamler J., Stamler R., Neaton J. D. Blood pressure, systolic and diastolic, and cardiovascular risks.US population data. Arch Intern Med. 1993; 153: 598–615
   PubMed Web of Science ®Google Scholar
• Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke and coronary heart disease. Part II,short-term reductions in blood pressure, overview of randomized trials intheir epidemiological context. Lancet. 1990; 335: 827–838
   PubMed Web of Science ®Google Scholar
• Herbert P. R., Moser M., Mayer J., et al. Recent evidence on drug therapy of mild to moderate hypertensionand decreased risk of coronary heart disease. Arch Intern Med. 1993; 153: 578–581
   PubMed Web of Science ®Google Scholar
• McMahon S., Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence in 1994. Trends Vasc Med. 1994; 4: 265–271
   Google Scholar
• Chobanian A. V., Alexander R. W. Exacerbation of atherosclerosis by hypertension. Potential mechanismsand clinical implications. Arch Intern Med. 1996; 156: 1952–1956
   PubMed Web of Science ®Google Scholar
• . Haffner S. M., Miettinen H., Gaskill S. P., et al. Metabolic precursors of hypertension. The San Antonio HeartStudy. Arch Intern Med. 1996; 156: 1994–2000
   PubMed Web of Science ®Google Scholar
• Suematsu C., Hayashi T., Fujii S., et al. Impaired fasting glucose and the risk of hypertension in Japanesemen between the 1980s and the 1990s. The Osaka Health Survey. Diabetes Care 1999; 22: 228–232
   PubMed Web of Science ®Google Scholar
• . McMahon S. W., MacDonald G. J., Blacket R. B. Plasma lipoprotein levels in treated and untreated hypertensivemen and women. The National Foundation of Australia Risk Factors PrevalenceStudy. Atherosclerosis 1985; 5: 391–396
   Google Scholar
• Castelli W. P., Anderson K. A population at risk. Prevalence of high cholesterol levelsin hypertensive patients in the Framingham Study. Am J Med. 1986; 80(Suppl. 2A)23–32
   PubMed Web of Science ®Google Scholar
• Williams R. R, Hunt S. C, Hopkins P. N., et al. Familial dyslipidemic hypertension: evidence from 58 Utah familiesfor a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259: 3579–3586
   PubMed Web of Science ®Google Scholar
• Austin M. A., Breslow J. L., Hennekens C. H., et al. Low-density lipoprotein subclass patterns and risk of myocardialinfarction. JAMA 1988; 260: 1917–1921
   PubMed Web of Science ®Google Scholar
• Stampfer M. J., Krauss R. M., Ma J., et al. A prospective study of triglyceride level, low-density lipoproteinparticle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882–888
   PubMed Web of Science ®Google Scholar
• Lamarche B., Tchernof A., Mauriège P., et al. Fasting insulin and apolipoprotein B levels and low-densitylipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961
   PubMed Web of Science ®Google Scholar
• The Fifth Report of the Joint National Committee on Detection,Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153: 152–183
   Google Scholar
• World Health Organization. Diabetes Mellitus. Technical Report Ser. No. 727. Report of a WHO StudyGroup. Geneva, World Health Organization, 1985
   Google Scholar
• Sentí M., Pedro-Botet J., Nogués X., et al. Influence of intermediate-density lipoproteins on the accuracyof the Friedewald formula. Clin Chem. 1991; 37: 1394–1397
   PubMed Web of Science ®Google Scholar
• The Expert Committee on the Diagnosis and Classification onDiabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classificationof Diabetes Mellitus. Diabetes Care 1997; 20: 1183–1197
   PubMed Web of Science ®Google Scholar
• Banegas J. R., Rodríguez-Artalejo F., de la Cruz Troca J. J., et al. Blood pressure in Spain. Distribution, awareness, control, andbenefits of a reduction in average pressure. Hypertension 1998; 32: 998–1002
   PubMed Web of Science ®Google Scholar
• Bonaa K. H., Thelle D. S. Association between blood pressure and serum lipids in a population.The Trömso Study. Circulation 1991; 83: 1305–1314
   PubMed Web of Science ®Google Scholar
• Stochmal A., Goldsztajn P., Hartwich M., et al. Very-low-density lipoprotein composition and endogenous insulinresponse in primary hypertension. J Hypertens 1993; 11(Suppl 5)S278–S279
   Google Scholar
• Havel R. J. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 1990; 81: 694–696
   PubMed Web of Science ®Google Scholar
• Ambrosch A., Mühlen I., Kopf D., et al. LDL size distribution in relation to insulin sensitivity andlipoprotein pattern in young and healthy subjects. Diabetes Care 1998; 21: 2077–2084
   PubMed Web of Science ®Google Scholar
• Kazumi T., Kawaguchi A., Hozumi T., et al. Low density particle diameter in young, nonobese, normolipidemicJapanese men. Atherosclerosis 1999; 142: 113–119
   PubMed Web of Science ®Google Scholar
• Austin M. A, Edwards K. L. Small, dense low density lipoproteins, the insulin resistancesyndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7: 167–171
   PubMed Web of Science ®Google Scholar
• Tchernof A., Lamarche B., Prud'Homme D., et al. The dense LDL phenotype. Association with plasma lipoproteinlevels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629–637
   PubMed Web of Science ®Google Scholar
• Griffin B. A., Freeman D. J., Tait G. W., et al. Role of plasma triglycerides in the regulation of plasma lowdensity lipoprotein (LDL) subfractions: relative contribution of small, denseLDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241–253
   PubMed Web of Science ®Google Scholar
• Criqui M. H., Golomb B. A. Epidemiologic aspects of lipid abnormalities. Am J Med. 1998; 105(1A)48S–57S
   PubMedGoogle Scholar
• Fagan T. C., Deedwania P. C. The cardiovascular dysmetabolic syndrome. Am J Med. 1998; 105(1A)77S–82S
   PubMedGoogle Scholar
• Slyper A. H., Zvereva S., Schectman G., et al. Insulin resistance is not a major determinant of low-densitylipoprotein particle size. Metabolism 1997; 46: 1275–1280
   PubMed Web of Science ®Google Scholar
• Meigs J. B., Nathan D. M., Wilson P. W.F., et al. Metabolic risk factors worsen continuously across the spectrumof nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med. 1998; 28: 524–533
   Google Scholar
• Björnholt J. V., Erikssen G., Hacer E., et al. Fasting blood glucose: an underestimated risk factor for cardiovasculardeath. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999; 22: 45–49
   PubMed Web of Science ®Google Scholar
• Balkau B., Shipley M., Jarrett R. J., et al. High blood glucose concentration is a risk factor for mortalityin middle-age nondiabetic men. 20-year follow-up in the Whitehall Study, theParis Prospective Study and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360–367
   PubMed Web of Science ®Google Scholar
• Genest J. J., McNamara J. R., Ordovas J. M., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a)abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792–802
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J., Sentí M., Nogués X., et al. Lipoprotein abnormalities in normolipidaemic patients with extracoronaryatherosclerosis: seeking new lipoprotein risk profiles. Nutr Metab Cardiovasc Dis. 1994; 4: 64–69
   Web of Science ®Google Scholar
• Hokanson J. E., Austin M. A. Plasma triglyceride level is a risk factor for cardiovasculardisease independent of high-density lipoprotein cholesterol level: a meta-analysisof population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219
   PubMedGoogle Scholar
• Grundy S. M. Small LDL, atherogenic dyslipidemia, and metabolic syndrome. Circulation 1997; 95: 1–4
   PubMed Web of Science ®Google Scholar
• Gardner C. D., Fortmann S. P., Krauss R. M. Association of small low density lipoprotein particles withthe incidence of coronary artery disease in men and women. JAMA 1996; 276: 875–881
   PubMed Web of Science ®Google Scholar
• Caixàs A., Ordóñez-Llanos J., de Leiva A., et al. Optimization of glycemic control by insulin therapy decreasesthe proportion of small dense LDL particles in diabetic patients. Diabetes 1997; 46: 1207–1213
   PubMed Web of Science ®Google Scholar
• Miller M. Is hypertriglyceridemia an independent risk factor for coronaryheart disease?. Eur Heart J. 1998; 19(Suppl H)18H–22H
   PubMedGoogle Scholar
• Kesäniemi Y. A. Relevance of the reduction of triglycerides in the preventionof coronary heart disease. Curr Opin Lipidol 1998; 9: 571–574
   PubMed Web of Science ®Google Scholar